The post-market review of the ODTP identified stigma, discrimination and cost as barriers to access, with patients borrowing money, eating less, and ultimately going without treatment. …
Post-market review identified cost and stigma as barriers to treatment
May 11, 2023 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 26 September
September 26, 2025 - - Podcast -
Waiting for any impact. Why the Albanese Government will hold fire on 'MFN'
September 26, 2025 - - Latest News -
Boehringer Ingelheim pushes for patient voices to lead policy reform
September 26, 2025 - - Latest News -
TGA consulting on the ongoing need for paper product information inserts
September 25, 2025 - - Latest News -
Gene therapy shows early promise in slowing Huntington’s Disease
September 25, 2025 - - Australian Biotech -
Federal minister to address AusBiotech International Conference as sector marks critical juncture
September 25, 2025 - - Australian Biotech -
Recce Pharmaceuticals begins patient dosing in pivotal diabetic foot infection trial
September 25, 2025 - - Australian Biotech